Mylan launches Hep C combination drug in India

The therapy offers a simplified treatment regimen that eliminates the need for interferon injections and ribavirin

Mylan Pharmaceuticals Private Limited, the Indian subsidiary of Mylan NV, has launched their generic Hepatitis C medicine under brand name MyHep LVIR in India.

This Ledipasvir/Sofosbuvir combination product is indicated for the treatment of Hepatitis C infection and offers a simplified treatment regimen that eliminates the need for interferon injections and ribavirin tablets, the company said.

The product is also a single-tablet regimen and requires a therapy course of just 12 weeks, compared with 24 to 48 weeks involving interferon and ribavirin, according to the company.

"Mylan recognises the urgent need to expand access to high quality, affordable Hepatitis C treatment options in India, where roughly 12 million people are infected with the virus. MyHep LVIR is an important addition to our growing Hepato Care segment in India," Mylan President Rajiv Malik said.

 

The launch of MyHep LIVR follows the launch of generic Sofosbuvir in India under the brand name MyHep in April, 2015. In September, 2014, Mylan entered into a licensing and technology transfer agreement with Gilead Sciences for non-exclusive rights to manufacture and distribute these Hepatitis C drugs in developing countries, including India.